|
CAS No. | 1062368-62-0 |
Chemical Name: | LDN-193189 HCl |
Synonyms: | LDN-193189 HCl;LDN193189 (Hydrochloride);4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyriMidin-3-yl)quinoline HCl;4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride;4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline hydrochloride (1:1) |
CBNumber: | CB02517951 |
Molecular Formula: | C25H23ClN6 |
Formula Weight: | 442.94332 |
MOL File: | 1062368-62-0.mol |
|
|
|
|
LDN-193189 HCl Chemical Properties,Usage,Production |
|
LDN-193189 HCl Preparation Products And Raw materials |
Raw materials
|
Preparation Products
|
LDN-193189 HCl Suppliers Global( 11)Suppliers |
Supplier | Tel | Fax | Email | Country | ProdList | Advantage |
Shanghai Boyle Chemical Co., Ltd.
| Mr Qiu 86-21-50182298(Domestic Market)Miss Xu 86-21-50180596(Abroad Market) | 86-21-57758967 | sales@boylechem.com | CHINA |
5604
|
55
|
Shangchem Co., Ltd.
| +86-21-68182121,+86 15000169545 | +86-21-68182121 | steven@shangchem.com | CHINA |
882
|
52
|
Syntechem Co.,Ltd
| Skype: syntechem18 | QQ 956912955 | qyh@syntechem.com we provide custom synthesis | CHINA |
29756
|
57
|
NCE Biomedical Co.,Ltd.
| 4000-027-021 |24 hour enquiry :+86-13986109188 |English:+86-15623472865 |Japanese:+81-08033611988 | +86-27-87599188 | sales@ncebiomed.com | CHINA |
1503
|
55
|
Shanghai Haoyuan Chemexpress Co., Ltd
| 86-21-58998590 | 86-21-53700326, 86-21-58998590 | sales@chemexpress.cn | CHINA |
10011
|
61
|
MedChemexpress LLC
| 609-228-6898 | 609-228-5909 | sales@medchemexpress.cn | USA |
4935
|
58
|
AdooQ BioScience, LLC
| +1 (866) 930-6790 | +1 (866) 333-9607 | info@adooq.com | USA |
2786
|
58
|
Hubei Jusheng Technology Co.,Ltd
| North:027-59599241,18871490274,QQ:1400878000 South:027-59531287,15727001360,QQ:1400878866 | ℡ 027-83861211 | 469501031@qq.com | CHINA |
10512
|
58
|
LETOPHARM LIMITED
| Please Email:sales@letopharm.com | +86-21-5106 2861 | sales@letopharm.com | CHINA |
2641
|
58
|
SPIRO PHARMA
| | - | eric_feng1954@126.com | CHINA |
9716
|
55
|
|
|
|
|